# A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

> **NCT01144403** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 8 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mitoxantrone
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01144403
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2016-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144403, "A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01144403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*